BRAF and metastatic colorectal cancer: <h4>Background</h4>Patients with metastatic colorectal cancer (mCRC) and <i>BRAF</i> V600E mutation have a poor prognosis, with a median progression-free survival (PFS) of only 5-7 months after initial therapy.